A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.

MLA

Maples-Keller, Jessica L., et al. “A Randomized Controlled Trial of 3,4-Methylenedioxymethamphetamine (MDMA) and Fear Extinction Retention in Healthy Adults.” Journal of Psychopharmacology, vol. 36, no. 3, Mar. 2022, pp. 368–77. EBSCOhost, https://doi.org/10.1177/02698811211069124.

APA

Maples-Keller, J. L., Norrholm, S. D., Burton, M., Reiff, C., Coghlan, C., Jovanovic, T., Yasinski, C., Jarboe, K., Rakofsky, J., Rauch, S., Dunlop, B. W., & Rothbaum, B. O. (2022). A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. Journal of Psychopharmacology, 36(3), 368–377. https://doi.org/10.1177/02698811211069124

Chicago

Maples-Keller, Jessica L, Seth D Norrholm, Mark Burton, Collin Reiff, Callan Coghlan, Tanja Jovanovic, Carly Yasinski, et al. 2022. “A Randomized Controlled Trial of 3,4-Methylenedioxymethamphetamine (MDMA) and Fear Extinction Retention in Healthy Adults.” Journal of Psychopharmacology 36 (3): 368–77. doi:10.1177/02698811211069124.